<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="35202">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01981720</url>
  </required_header>
  <id_info>
    <org_study_id>PB-102-F03</org_study_id>
    <nct_id>NCT01981720</nct_id>
  </id_info>
  <brief_title>Extension Study of PRX-102 for 24 Months</brief_title>
  <official_title>A Multi Center Extension Study of PRX-102 Administered by Intravenous Infusions Every 2 Weeks for 24 Months to Adult Fabry Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Protalix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Protalix</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the ongoing safety, tolerability, and efficacy parameters of PRX-102 in adult
      Fabry patients who have successfully completed treatment with PRX-102 in studies PB-102-F01
      and PB-102-F02. Patients will be enrolled  to receive the same dose of PRX-102 (0.2 mg/kg,
      1.0 mg/kg, 2.0 mg/kg), as an intravenous infusion every 2 weeks for 24 Months.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Treatment emergent adverse events</measure>
    <time_frame>Every two weeks for 24 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Fabry Disease</condition>
  <arm_group>
    <arm_group_label>1.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PRX-102 1.0 mg/kg IV every 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PRX-102 2.0 mg/kg IV every 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.2 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PRX-102 0.2 mg/kg IV every 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRX-102</intervention_name>
    <arm_group_label>1.0 mg/kg</arm_group_label>
    <arm_group_label>2.0 mg/kg</arm_group_label>
    <arm_group_label>0.2 mg/kg</arm_group_label>
    <other_name>chemically modified human alpha galactosidase</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Completion of study PB-102-F02

          -  The patient signs informed consent

          -  Female patients and male patients whose co-partners are of child-bearing potential
             agree to use a medically acceptable method of contraception, not including the rhythm
             method. Acceptable methods of contraception include hormonal products, intrauterine
             device, or male or female condoms. Contraception should be used for 1 month after
             treatment termination.

        Exclusion Criteria:

          -  Pregnant or nursing

          -  Presence of any medical, emotional, behavioral or psychological condition that, in
             the judgment of the Investigator and/or Medical Director, would interfere with the
             patient's compliance with the requirements of the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Einat Almon, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Protalix Ltd</affiliation>
  </overall_official>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 5, 2013</lastchanged_date>
  <firstreceived_date>November 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fabry Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
